Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

N Engl J Med. 2021 Nov 11;385(20):e69. doi: 10.1056/NEJMc2107661.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Hyperoxaluria, Primary* / genetics
  • Hyperoxaluria, Primary* / therapy
  • RNA Interference
  • RNAi Therapeutics*

Supplementary concepts

  • Primary hyperoxaluria type 1